Altamira Therapeutics (FRA:2QA) OCF Margin %: 0.00% (As of Jun. 2025)


FRA:2QA Altamira Therapeutics Ltd FRA:2QA
30 GF Score
Price €948.00
! 4 Warning Signs
View Full Analysis

What is Altamira Therapeutics OCF Margin %?

Altamira Therapeutics FRA:2QA 30 OCF Margin % is 0.00% as of Jun. 2025. GuruFocus rates FRA:2QA with a GF Score™ of 30/100. The stock has 4 warning signs investors should review. Among 950 Biotechnology companies, Altamira Therapeutics ranks worse than 105263.05% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Altamira Therapeutics's Cash Flow from Operations for the six months ended in Jun. 2025 was €-1.20 Mil. Altamira Therapeutics's Revenue for the six months ended in Jun. 2025 was €0.00 Mil. Therefore, Altamira Therapeutics's OCF Margin % for the quarter that ended in Jun. 2025 was 0.00%.

As of today, Altamira Therapeutics's current OCF Yield % is -1,501.40%.

The historical rank and industry rank for Altamira Therapeutics's OCF Margin % or its related term are showing as below:


FRA:2QA's OCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -65.71
* Ranked among companies with meaningful OCF Margin % only.

Altamira Therapeutics OCF Margin % Related Terms

Altamira Therapeutics OCF Margin % Historical Data

* Premium members only.

The historical data trend for Altamira Therapeutics's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Altamira Therapeutics OCF Margin % Chart

Altamira Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
OCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Altamira Therapeutics Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:2QA
30GF Score
Altamira Therapeutics Ltd FRA:2QA
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Altamira Therapeutics OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Altamira Therapeutics's OCF Margin for the fiscal year that ended in Dec. 2024 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2024 )/Revenue (A: Dec. 2024 )
=-5.839/0
= %

Altamira Therapeutics's OCF Margin for the quarter that ended in Jun. 2025 is calculated as

OCF Margin=Cash Flow from Operations (Q: Jun. 2025 )/Revenue (Q: Jun. 2025 )
=-1.2/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
Altamira Therapeutics (FRA:2QA) has a OCF Margin % of 0.00% as of Jun. 2025. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Altamira Therapeutics and its competitors. According to the industry distribution chart, Altamira Therapeutics ranks #999999 out of 950 companies in the Biotechnology industry.
Is Altamira Therapeutics' OCF Margin % too high?
Altamira Therapeutics' current OCF Margin % is 0.00%. Based on the distribution chart, Altamira Therapeutics ranks #999999 out of 950 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Altamira Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Altamira Therapeutics' OCF Margin % compare to IOBTQ and SCPX?
According to the Biotechnology industry distribution chart, Altamira Therapeutics ranks #999999 out of 950 companies for OCF Margin %. This places Altamira Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Altamira Therapeutics and its competitors. Altamira Therapeutics's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Altamira Therapeutics stock overvalued right now?
Altamira Therapeutics (FRA:2QA) has a current OCF Margin % of 0.00%. The current OCF Margin % is 0.00%. Altamira Therapeutics' overall GF Score™ is 30/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Altamira Therapeutics (FRA:2QA), the current OCF Margin % is 0.00% as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Altamira Therapeutics Business Description

Other Exchanges CYTOF:USA
Address 2 Church Street, Clarendon House, Hamilton, BMU, HM11
Altamira Therapeutics Ltd is developing and supplying peptide-based nanoparticles for safe and effective RNA delivery to extrahepatic tissues (xPhore platform). The Company is offering biopharmaceutical companies access to its technology for use with their own RNA molecules under collaboration and licensing agreements. The xPhore platform is suitable for various RNA modalities - OligoPhore for oligonucleotides, SemaPhore for mRNA, CycloPhore for circRNA - as well as for DNA (GenePhore). In addition, Altamira Therapeutics is pursuing two proprietary flagship development programs using OligoPhore: AM-401 for KRAS driven cancer and AM-411 for rheumatoid arthritis. Geographically, the companies operates in United Staes and Switzerland.
30GF Score

Get the complete analysis for FRA:2QA

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€948.00
Price